References
- Anghelescu I.G, Edwards D, Seifritz E, Kasper S. (2018) ‘Stress management and the role of Rhodiola rosea: a review’ International Journal of Psychiatry in Clinical Practice Vol 22 Issue 4 Pages:242–252
- Amsterdam JD, Panossian AG. ‘Rhodiola rosea L. as a putative botanical antidepressant’ Phytomedicine. 2016 Jun 15;23(7):770–83. doi: 10.1016/j.phymed.2016.02.009. Epub 2016 Feb 24
- Beck AT, Steer RA, Ball R, Ranieri W (December 1996). ‘Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients’. Journal of Personality Assessment. 67 (3): 588–97. doi: 10.1207/s15327752jpa6703_13. PMID 8991972
- Brekhman I. I.; Dardymov I. V. (1969) ‘New substances of Plant Origin which Increase Nonspecific Resistance’. (Annual Review of Pharmacology. 9: 419–430)
- Cropley M, Banks AP, Boyle J ‘The Effects of Rhodiola rosea L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms’ Phytother Res. 2015 Dec;29(12):1934–9.
- Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. ‘Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression.’ Nord J Psychiatry. 2007;61(5):343–8. Erratum in: Nord J Psychiatry. 2007;61(6):503.
- Dwyer AV, Whitten DL, Hawrelak JA ‘Herbal medicines, other than St. John’s Wort, in the treatment of depression: a systematic review.’ Altern Med Rev. 2011 Mar;16(1):40–9. Review.
- European Medicines Agency (2008) ‘Reflection Paper on the Adaptogenic Concept’ Committee on Herbal Medical Products (PDF) 8 May 2008.
- Evstavieva L, Todorova M, Antonova D, Staneva J (2010). ‘Chemical composition of the essential oils of Rhodiola rosea L. of three different origins’ Rharmacogn Mag. 6 (24): 256–258.
- Guy, William (1976). ‘Clinical Global Impressions’ ECDEU Assessment Manual for Psychopharmacology—Revised. Rockville, MD: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol; Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs. pp. 218–222.
- Hamilton M. (1959) ‘The assessment of anxiety states by rating.’ Br J Med Psychol 1959; 32:50–55.
- Hamilton, M (1960). ‘A rating scale for depression’. Journal of Neurology, Neurosurgery, and Psychiatry. 23: 56–62. doi: 10.1136/jnnp.23.1.56. PMC 495331. PMID 14399272.
- Hungk SK, Perry R, Ernst E (2011) ‘The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials.’ Phytomedicine. 2011 Feb 15;18(4):235–44. doi: 10.1016/j. phymed.2010.08.014. Epub 2010 Oct 30.
- Ishaque S, Shamseer L, Bukutu C, Vohra S (2012) ‘Rhodiola rosea for physical and mental fatigue: a systematic review.’ BMC Complement Altern Med. 2012 May 29;12:70. doi: 10.1186/1472-6882-12-70.
- Jacob Cohen (1988) ‘Statistical Power Analysis for the Behavioral Sciences. (2nd ed.), New Jersey: Lawrence Erlbaum Associates.
- Lishmanov I, Trifonova Z, Tsibin AN, Maslova LV, Dement’eva LA (1987) ‘[Plasma beta-endorphin and stress hormones in stress and adaptation]’. Biull Eksp Biol Med. 1987 Apr;103(4):422–4.
- Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD ‘Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial’ Phytomedicine. 2015 Mar 15;22(3):394–9.
- Mao Y, Li Y, Yao N (2007) ‘Simultaneous determination of salidroside and tyrosol in extracts of Rhodiola L. By microwave assisted extraction and high-performance liquid chromatography’. Journal of Pharmaceutical and Biomedical Analysis.45 (3): 510–5.
- Mattioli L, Funari C, Perfumi M (2008) ‘Effects of Rhodiola rosea L. extract on behavioural and physiological alterations induced by chronic mild stress in female rats.’ Journal of Psychopharmacology. 2008 May 30.
- McNair, D.; Lorr, M.; Doppleman, L. (1971). POMS Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service.
- Moher D, Liberati A, Tetzlaff J, Altman DG The Prisma Group (2009) ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.’ Journal of Clinical Epidemiology 2009
- Montgomery SA, Asberg M (April 1979). ‘A new depression scale designed to be sensitive to change’. British Journal of Psychiatry. 134 (4): 382–89. doi: 10.1192/bjp.134.4.382. PMID 444788.
- Olsson EM, Von Sheele B, Panossian AG (2009) ‘A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Standardised Extract SHR-5 of the Roots of Rhodiola rosea in the Treatment of Subjects with Stress-Related Fatigue’. Planta Med. 2009 Feb;75(2):105–12.
- Panossian A, Wikman G, Hambardzumyan M, Hovhanissyan A 2007 ‘The Adaptogens Rhodiola and Schizandra Modify the Response to Immobilization Stress in Rabbits by Suppressing the Increase of Phosphorylated Stress-activated Protein Kinase, Nitric Oxide and Cortisol’ Drug Target Insights 2007; 2: 39–54.
- Panossian A, Wikman G, Sarris J (2010). ‘Rosenroot (Rhodiola rosea): Traditional use, Chemical composistion, pharmacology and clinical efficacy’. Phytomedicine. 2010 Jun;17(7):481–93.
- Panossian A, Wikman G, (2010) ‘Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms Associated with Their Stress—Protective Activity Pharmaceuticals (Basel).’ 2010 Jan; 3(1): 188–224.
- Perfumi M, Mattioli L (2007) ‘Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice.’ Phytotherapy Research. 2007 Jan;21(1):37–43.
- Plants for a Future 2012
https://pfaf.org/user/Plant.aspx?LatinName=Rhodiola+rosea - Ross SM ‘Rhodiola rosea (SHR-5), Part 2: A Standardized Extract of Rhodiola rosea Is Shown to Be Effective in the Treatment of Mild to Moderate Depression’ Holist Nurs Pract. 2014 May–Jun;28(3):217–21.
- Sarris J ‘Herbal medicines in the treatment of psychiatric disorders: a systematic review.’ Phytother Res. 2007 Aug;21(8):703–16. Review.
- Sarris J, Panossian A, Schwitzer I, Stough C, Scholey A ‘Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence.’ Eur Neuropsychopharmacol. 2011 Dec;21(12):841–60. doi: 10.1016/j.euroneuro.2011.04.002. Epub 2011 May 23. Review.
- Spasov A.A., Wikman G.K., Mandrikov V.B., Mironova A., Neumoin V.V.NEUMOIN (2000) ‘A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodio/a rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen.’ Phytomedicine, Vol. 7(2), pp. 85–89.
- Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
- Steyer R., Schwenkmezger P., Notz P., & Eid M. (1997). The multidimensional mental state questionnaire: Manual. Gottingen: Hogrefe.
- Sullivan M, Karlsson J, Ware J. The Swedish SF-36 health survey – I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995; 41 1349–58
- Tao H, Wu X, Cao J, Peng Y, Wang A, Pei J, Xiao J, Wang S, Wang Y. ‘Rhodiola species: A comprehensive review of traditional use, phytochemistry, pharmacology, toxicity, and clinical study.’ Med Res Rev. 2019 Sep;39(5):1779–1850. doi: 10.1002/med.21564. Epub 2019 Jan 16.
- Van Diermen D, Maston A, Bravo J, Reist M, Carrupt PA, Hostettmann K (2009) ‘Monoamine oxidase inhibition by Rhodiola rosea L. roots.’ J Ethnopharmacol. 2009 Mar 18;122(2):397–401. doi: 10.1016/j.jep.2009.01.007. Epub 2009 Jan 9.
- Yang S.J., Yu H.Y., Kang D.Y., Ma Z.Q., Qu R., Fu Q., Ma S.P. Antidepressant-like effects of salidroside on olfactory bulbectomy-induced pro-inflammatory cytokine production and hyperactivity of HPA axis in rats. Pharmacol. Biochem. Behav, 124 (2014), pp. 451–457.
- Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. ‘Herbal Medicine for Depression and Anxiety: A Systematic Review with Assessment of Potential Psycho-Oncologic Relevance’. Phytother Res. 2018 May;32(5):865–891. doi: 10.1002/ptr.6033. Epub 2018 Feb 21. Review.